GRTS - Gritstone Oncology, Inc.
| Previous Close | 22.18 |
| Open | 22.04 |
| Bid | 0.00 x 1300 |
| Ask | 30.00 x 800 |
| Day's Range | 19.92 - 23.90 |
| 52 Week Range | 11.22 - 32.90 |
| Volume | 177,048 |
| Avg. Volume | 182,574 |
| Market Cap | 598.479M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -28.35 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.67 |
- GlobeNewswire•21 hours ago
Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE™
EMERYVILLE, Calif., Dec. 17, 2018 -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to.
- Motley Fool•3 days ago
3 Biotechs Gilead Sciences Could Buy in March
With a new CEO from Roche on the way, these companies' odds of being acquired just rose a notch.
- American City Business Journals•5 days ago
Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay
Orchard Therapeutics is tackling "bubble baby" disease and other rare genetic conditions with gene therapy.
- GlobeNewswire•8 days ago
Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead
Gritstone Oncology, Inc. (GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it is advancing its bispecific antibody (BiSAb) program under the direction of newly appointed vice president of Antibody Therapeutics, Jonah Rainey, Ph.D. The BiSAb program leverages the company’s artificial intelligence platform, EDGETM, for the identification and prioritization of highly tumor-specific antigens, including neoantigens, shared between patients with various solid tumors. To enable the development of BiSAb therapeutics directed to solid tumors, Gritstone has discovered antibodies with selective and high-affinity binding to tumor-specific peptide-HLA (Human Leukocyte Antigen) complexes (HLAp).
- American City Business Journals•22 days ago
Here's how much better insiders have profited from this year's IPO boom
If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.
- GlobeNewswire•last month
Gritstone Oncology Reports Third Quarter 2018 Financial Results and Recent Business Highlights
Successful Initial Public Offering Raises $95.6 Million in Net Proceeds EMERYVILLE, Calif., Nov. 14, 2018 -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage.
- American City Business Journals•3 months ago
24 Bay Area companies have gone public so far this year. Here's how they've done.
The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.
- MarketWatch•3 months ago
Gritstone Oncology expects to begin trading today, prices at $15 per share
Gritstone Oncology Inc. has priced its initial public offering at $15 per share, at the top of a previously-set range, and will offer 6.66 million shares, more than previous plans to offer 6.07 million shares. The cancer-focused biotech company expects to begin trading on Friday on Nasdaq under the ticker "GRTS," and now expects gross proceeds of about $100 million. The offering should close on Oct. 2, the company said. Gritstone develops cancer immunotherapies, which use the body's immune system to fight cancer, and its products are specifically geared towards solid tumors. It has four products so far in extremely early development, and hopes to submit an application in the second half of this year to move one, Granite-001, into a phase 1/2 clinical trial. This year is considered a good time for biotechnology initial public offerings, with a number of buzzy companies going public in recent months. The SPDR S&P Biotech ETF has surged 13% year-to-date, compared with a 9% rise in the S&P 500 and a nearly 7% rise in the Dow Jones Industrial Average .
- The Wall Street Journal•3 months ago
[$$] Gritstone Oncology Prices Upsized IPO at Top of Range
Gritstone Oncology Inc. sold more shares than expected at the high end of the anticipated price range of its initial public offering, raising about $100 million.
- GlobeNewswire•3 months ago
Gritstone Oncology Announces Pricing of Initial Public Offering
EMERYVILLE, Calif., Sept. 27, 2018-- Gritstone Oncology, Inc. today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, ...
- Benzinga•3 months ago
The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...
